Abstract
The objective of this paper was to study the effect of antibody-directed targeting of S.aureus by comparing the activities of lysostaphin conjugated to biodegradablepolylactide nanoparticles (NPs) in the presence and in the absence of co-immobilizedanti-S. aureus antibody. Lysostaphin–antibody–NP conjugates were synthesizedthrough physical adsorption at different enzyme:antibody:NP ratios. The synthesizedenzyme–NP conjugates were characterized by means of dynamic light scatteringand zeta potential analysis, and the total protein binding yield on the NPs wascharacterized using Alexa Fluor 350 and 594 dyes for the S. aureus antibody andlysostaphin respectively. We observed enhanced antimicrobial activity for bothenzyme-coated and enzyme–antibody-coated NPs for lysostaphin coatings corresponding to ∼ 40% of the initial monolayer and higher compared to the free enzyme case (p < 0.05). At the highest antibody coating concentration, bacterial lysis rates for antibody-coatedsamples were significantly higher than for lysostaphin-coated samples lacking the antibody (p < 0.05). Such enzyme–NP conjugates thus have the potential for becoming novel therapeuticagents for treating antibiotic-resistant S. aureus infections.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
